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Abstract 
Until recently, the main treatment for 
pemphigus has been systemic 
corticosteroids, usually administered at high 
doses with consequent side-effects.  Lately, 
the biological agent rituximab has been 
introduced as an effective treatment for this 
condition.   
This article describes seven cases of 
pemphigus successfully treated with 
rituximab in Malta and discusses the 
benefits and drawbacks of this novel 
treatment modality. 
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Introduction 
Pemphigus is an uncommon but serious 
cutaneous immunobullous disorder, 
generally of the middle-aged, where 
blistering occurs intraepithelially, at the 
level of the intercellular desmosomes due to 
autoantibodies (typically to desmoglein 3 in 
mucosal-dominant disease and to 
desmoglein 1 and desmoglein 3 in 
mucocutaneous disease).1-2  The pathogenic 
role of anti-desmoglein autoantibodies is 
evidenced by development of pemphigus 
vulgaris-like lesions in neonatal mice 
infused with anti-desmoglein IgG and 
occurrence of a pemphigus vulgaris-like 
syndrome in genetically-modified 
desmoglein 3 knockout mice.3
In pemphigus vulgaris, blistering may 
appear in both the skin and mucosae.  Skin 
blisters and erosions occur in the majority of 
cases at some stage, mostly on the scalp, 
face, neck, back and upper chest.4 Mucosal 
disease is the only manifestation in some 
cases.  Apart from being life-threatening, 
pemphigus has a major impact on patients’ 
quality of life, causing significant pain and 
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discomfort, especially in cases with oral 
involvement. 
Before the advent of corticosteroids, 
pemphigus mortality reached 75% with 
many patients dying of sepsis, 
Staphylococcus aureus being the 
commonest pathogen on diseased skin.5-6  
Until recently, the mainstay of therapy has 
been systemic steroids combined with 
steroid-sparing agents such as azathioprine,7 
mycophenolate sodium8 and 
cyclophosphamide.9  Other treatments 
employed with variable efficacy include 
cyclosporine,10 intravenous 
immunoglobulins,11 photodynamic 
therapy,12 immunoadsorption13 and 
plasmapheresis.14  There are no large 
randomised controlled trials comparing 
different treatment regimens so data is 
limited to that derived from retrospective 
studies.8  Modern pemphigus treatment has 
decreased mortality to under 5%, however, 
the need for steroids to control disease in 
most cases exposes patients to significant 
side-effects.9 
Rituximab is an IgG1 chimeric 
mouse/human anti CD-20 antibody that 
causes antibody-mediated B–cell lysis.15 It 
has recently been shown to be effective for 
treating pemphigus and appears particularly 
useful in patients in whom traditional 
therapy is insufficient or inappropriate.16 
The drug has become available locally and 
this article describes its use in seven cases of 
pemphigus vulgaris in Maltese patients.  
Figure 1: H&E x40 - Histology of skin biopsy of Case 1 showing the split just above the basal 
layer, with tombstone morphology of the remaining basal cells and acantholytic cells in the 
blister lumen 
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Case series 
We report seven cases of pemphigus 
vulgaris treated with rituximab in Malta 
between 2013 and 2016.  Four patients were 
male and three were female with a mean age 
at diagnosis of 57 years (range 44-70 years). 
The main presenting features were blisters, 
superficial ulcers and erosions on the trunk 
and head and neck.  Five patients had 
painful ulcers and erosions in the oral 
mucosa.  Other symptoms reported included 
hoarseness, odynophagia, nosebleeds, 
auditory canal erosions and crusted plaques 
on the trunk.   
All cases were confirmed 
histologically, with intraepidermal clefting 
and acantholysis seen in all cases. Direct 
immunofluorescence was available in five 
cases, all of which showed typical 
intercellular C3 and IgG deposition in the 
epidermis.  The histology of one of our 
patients is shown in Figure 1. 
Various systemic treatments were given 
before administration of rituximab. These 
included oral and intravenous steroids, 
azathioprine, mycophenolate sodium, 
methotrexate, dapsone, intravenous 
immunoglobulins and colchicine. 
The rituximab regimens used in our 
patients were once-weekly 500mg 
intravenous infusions for four weeks or two 
intravenous infusions of 1g two weeks apart. 
Excellent responses were reported in all 
cases after a few weeks.  Three patients 
entered remission after only one rituximab 
cycle.  Four patients had recurrences after an 
average of six months but the symptoms 
were milder in all cases.  Of these patients, 
two went into remission after the second 
cycle of rituximab whilst another patient 
went into remission after the third cycle of 
rituximab.  One patient had a very mild 
recurrence which was treated successfully 
with intravenous immunoglobulin. Some 
low-dose immunosuppressive treatment 
continues to be required to maintain control 
in all patients.  This includes mycophenolate 
combined with low-dose prednisolone (5mg 
daily), azathioprine in isolation, and 
azathioprine combined with low-dose 
prednisolone (5mg daily).  Improvement of 
cutaneous features following rituximab in 
one of our patients is shown in Figure 2.   
Figure 2: Case 5 before (left) and after (right) rituximab therapy, showing resolution of 
extensive blistering and erosions on the back
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Table 1: Details of 7 cases of pemphigus vulgaris treated in Malta with rituximab between 2013 and 2016 (IVIG – 
intravenous immunoglobulins) 
Age at 
diagnosis 
(years) 
Sex Symptoms at 
presentation 
Histology & 
Immunofluorescence (IF) 
Treatment attempted 
before rituximab 
Rituximab 
regimen/doses used 
Response Rituximab side-
effects  
Case 1 51 F • Painful ulcers
on hard palate
and buccal
mucosa
• Nose bleeds
• Persistent sore
throat
• Auditory canal
erosions
• Suprabasal blistering
with acantholytic cells in
intraluminal bulla
• Dilapidated brick wall
appearance
• IF – weak intercellular
positive staining in basal
layers for C3 and IgG
• Prednisolone +
azathioprine
• Prednisolone + iv
methylprednisolone +
mycophenolate
sodium
- 4 once-weekly
500mg
infusions
- 1 g 2 weeks
apart for 2
subsequent
infusions
After 1st – dramatic 
improvement + minor 
recurrence after 6 months 
After 2nd – slight 
recurrence after 1 year 
After 3rd - remission  
Minor reaction during 
3rd cycle -  pruritic 
erythema on the hands, 
spreading to arms and 
face; no systemic 
symptoms 
Case 2 53 M • Odynophagia
• Mouth ulcers
• Hoarseness
• Blisters on left
supraclavicular
area and chest
• Intraepidermal clefting
with acantholysis
• Basal keratinocytes still
attached to basement
membrane with a
tombstone appearance
• Sparse chronic
inflammatory cell
infiltrate including a few
eosinophils
• IF – intercellular C3 and
IgG deposition in
epidermis
• Prednisolone
• Prednisolone +
azathioprine
- 4 once-weekly
500mg
infusions,
- 1 g 2 weeks
apart for 1
subsequent
infusion
After 1st –improvement + 
minor recurrence after a 
few weeks 
After 2nd – remission 
Nil 
Case 3 44 M • Blisters over
scalp, chest and
abdomen
• Suprabasal acantholysis
• IF - intercellular C3 anf
IgG deposition in
epidermis
• Dapsone
• Dapsone +
prednisolone
• IVIG
- 4 once-weekly
500mg
infusions
- 2 500mg
infusions
After 1st – improvement + 
flare after 9 months 
After 2nd – remission 
Nil 
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Case 4 50 F • Extensive
painful oral
ulcers
• Suprabasal acantholysis
with basal keratinocytes
remaining intact with a
tombstone appearance
• Superimposed viral
changes within nuclei of
keratinocytes implying
superimposed herpes
simplex
• IF – IgG deposition in
epithelium
• Prednisolone +
azathioprine
- 4 once-weekly
500mg
infusions
Remission Nil 
Case 5 63 M • Scaly eruption
over chest
• Plaques on face,
scalp, neck and
upper trunk,
limbs and
thighs
• Erosions in oral
mucosae
• Blisters on
lower back
• Intraepidermal blister
with partially preserved
basal keratinocytes
• Mild chronic inflamation
with a few eosinophils
• IF - equivocal IgG and
C3 deposition
intercellularly in the
epidermis
• Topical clobetasone
• Prednisolone
• Azathioprine
- 1g 2 weeks
apart
Recurrence with facial 
bullae, for which he was 
given IVIG, then entered 
remission 
Nil 
Case 6 69 F • Mouth ulcers
• Blisters on
lower back
• Mucosal hyperplasia +
suprabasilar clefting
• Acantholysis
• Basal keratinocytes with
a tombstone appearance
• IF – Not available
• Prednisolone +
azathioprine
- 1g 2 weeks
apart
Remission Nil 
Case 7 70 M • Persistent lip
ulcer
• Blister over scar
• Submucosal epithelial
split with hobnail type
mucosal cells
• Underlying haemorrhage
• IF – Not available
• Prednisolone
• Prednisolone +
azathioprine
• Prednisolone +
colchicine
• Prednisolone + IVIG
• Prednisolone + IVIG
+ dapsone
• IVIG + Dapsone
- 1g 2 weeks
apart
Remission Nil 
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Rituximab was well tolerated in all 
cases with only one patient developing a 
significant side-effect, namely pruritic 
erythema on the hands spreading to the arms 
and face without systemic symptoms during 
the third treatment cycle.  The infusion was 
stopped and the erythema resolved without 
treatment within two hours.   
Details of the seven cases are shown in 
Table 1. 
Discussion 
The mechanism of rituximab action is 
not yet fully-understood.  Although it 
decreases production of pathogenic auto-
antibodies, it does not affect levels of 
protective antibodies and so total antibody 
titre remains unchanged.  One theory for this 
is that whereas pathogenic autoantibody-
producing plasma cells are CD-20 positive 
and thus targeted by rituximab, protective 
plasma cells are CD-20 negative and hence 
not targeted.17  
Rituximab entered clinical use in the 
1990s, mainly to treat lymphoma and 
rheumatoid arthritis.  Other indications 
include ANCA-positive vasculitis, systemic 
lupus erythematosus, dermatomyositis and 
primary Sjogren’s syndrome.15 It was first 
used in the context of autoimmune bullous 
diseases in 1999 by Heizmann et al who 
reported a case of paraneoplastic pemphigus 
successfully treated by rituximab, and is 
increasingly being used worldwide in the 
management of pemphigus.18  Locally it was 
first used to treat pemphigus in 2013.  Other 
autoimmune bullous diseases for which 
treatment with rituximab has been employed 
include bullous pemphigoid, mucous 
membrane pemphigoid and epidermolysis 
bullosa acquisita.19 
Rituximab has a half-life of around 20 
days, and is given by slow intravenous 
infusion.15 The dosing protocols most 
commonly used are the lymphoma protocol, 
consisting of four weekly infusions of 375 
mg/m2 and the rheumatoid arthritis protocol, 
where two infusions of 1g are given two 
weeks apart.2  However, there is no scientific 
rationale reported in the literature as to why 
these two protocols should be used in 
pemphigus.  The protocols appear 
equivalent in terms of remission and relapse 
rates although remission may be more 
prolonged with higher rituximab doses.20  
Rituximab may be administered in 
conjunction with intravenous 
immunoglobulins, with early studies of such 
combination treatment reporting promising 
results.16,21 
Infusion reactions have been reported 
in 25% of individuals receiving their first 
rituximab dose.  Such reactions tend to be 
mild to moderate in nature, the severity 
decreasing with subsequent doses.  The risk 
of infusion reactions may be reduced by 
premedication (including analgesics, 
antihistamines and steroids).15 In our series, 
a minor cutaneous infusion reaction 
occurred in one patient, during her eighth 
infusion, despite premedication with 
prednisolone, chloremphenamine and 
paracetamol. Other more serious possible 
adverse events include an increased 
infection risk (including opportunistic 
pathogens), progressive multifocal 
leukoencephalopathy, cytopenia and cardiac 
events in individuals with underlying 
cardiac problems.  The incidence of severe 
adverse effects does not appear to be 
influenced by the protocol used.20  
Paradoxical worsening of pemphigus 
following rituximab infusion has also been 
reported.22 
Contraindications to rituximab include 
severe immunosuppression, active infection, 
uncontrolled cardiac disease and recent live 
vaccination.  Before starting rituximab, 
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patients should be screened for cardiac 
disease, current or previous infections that 
could be reactivated (e.g. tuberculosis and 
viral hepatitis) and vaccination status 
(especially for pneumococcal disease and 
influenza) checked. Viral hepatitis is not an 
absolute contraindication, however, it must 
be looked out for, and a decision on whether 
or not rituximab may be prescribed taken in 
the light of expert hepatological advice.15
Due to its reported adverse effects on 
pregnancy, women are advised to avoid 
pregnancy during treatment and for at least 
12 months afterwards.15,23 
Patients treated with rituximab should 
be monitored for signs of infection and 
neurological complications.  Basic blood 
tests, including full blood count, renal 
profile and liver enzyme levels should be 
assessed regularly.  It is also recommended 
that serum immunoglobulins and 
lymphocyte subsets are checked prior to 
each subsequent dose.15 
Despite not being a new drug per se, 
specific long-term complications, if any, of 
rituximab use in pemphigus, have yet to be 
described.  Currently, dermatologists are 
using the drug in patients unresponsive to 
conventional therapy or in patients in whom 
conventional therapy is contraindicated 
because of adverse effects.16  It may also be 
used as a first-line treatment, although the 
exact place of rituximab in the routine 
management of pemphigus has yet to be 
determined.2  Undoubtedly a major 
drawback of the drug is its cost, which, like 
other biological agents, is much higher than 
that of conventional treatment.  In fact, the 
current drug cost of four 500mg doses of 
rituximab is estimated to be €5710.00 
(€1427.50 x4) (Mr. Joe Sciberras, Senior 
Pharmacist, Sir Paul Boffa Hospital, 
personal communication). 
Apart from controlling relapses of 
pemphigus,21 rituximab may also produce 
long-term disease remission.  A study in 
India on 25 patients (21 with pemphigus 
vulgaris and four with pemphigus foliaceus) 
reported a complete remission rate of 88% 
following rituximab, complete remission 
defined as absence of lesions for two 
months.  Furthermore, this study reported a 
decrease in the cumulative corticosteroid 
dose of 69.6% when compared to patients 
treated with prednisolone alone.2 Another 
study20  reported complete remission rates of 
76%, with a mean time of 5.8 months to 
remission and a mean duration of 14.5 
months of remission; relapse rates were 
reported to be 40%.  However, it is 
important to consider original disease 
severity when interpreting such statistics.  In 
our cases rituximab clearly had a major 
suppressive effect on disease activity. It was 
well tolerated apart from a minor cutaneous 
reaction in one patient. 
Conclusion 
The results of rituximab therapy of 
pemphigus are promising.  The drug appears 
to be generally well tolerated and may 
produce long-term remission, reducing the 
need for systemic steroids in affected 
patients.  Further experience should help 
define the place of rituximab in the 
management of pemphigus. 
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